Organized breast screening: Answers to recurring controversies  by Ceugnart, L. et al.
Diagnostic and Interventional Imaging (2014) 95, 355—359
REVIEW / Breast imaging
Organized  breast  screening:  Answers  to
recurring controversies
L.  Ceugnarta,∗,  M.  Deghayeb,  P.  Venninc, S.  Haberd,
S.  Taieba
a Imaging  Department,  Oscar-Lambret  Regional  Cancer  Center,  3,  rue  Frederic-Combemale,
59000  Lille,  France
b Medical  Imaging  Center,  89,  rue  du  General-de-Gaulle,  77230  Dammartin  en  Goele,  France
c Breast  Department,  Oscar-Lambret  Regional  Cancer  Center,  59000  Lille,  France





Abstract  The  reduction  in  mortality  speciﬁcally  from  breast  cancer,  demonstrated  in  the
major  meta-analyses  in  the  1980s  resulted  in  public  health  breast  cancer  screening  programs
being  set  up  in  many  countries,  including  France.  Recent  publications  have  challenged  the
usefulness  of  screening,  by  insisting  in  particular  on  the  negative  effects  of  overdiagnosis  and
the  lack  of  any  signiﬁcant  impact  on  mortality.  From  analysis  of  the  literature  and  particularly
independent reviews  published  in  2012,  we  provide  some  answers  for  doctors  faced  with  the
legitimate  concerns  of  women.  These  studies  conﬁrm  that  screening  in  the  right  age  group
reduces  speciﬁc  mortality  by  at  least  20%  at  a  cost  of  overdiagnosis  estimated  at  between  1
and  15%.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Organized  mammography  screening  for  breast  cancer  next  year  celebrates  10  years  of
use  throughout  French  territory.  The  organization,  conceived  in  the  1980s  and  unique  in  the
world  among  other  things  for  being  decentralized  and  providing  the  possibility  of  producing
an  immediate  diagnostic  assessment  (IDA),  has  been  proved  to  be  effective,  particularly
according  to  the  European  early  evaluation  criteria  of  the  quality  of  the  program  [1].  The
rate  of  participation  alone  is  not  as  high  as  was  expected  since  at  the  present  time  it  is  on
average  only  52%,  instead  of  the  recommended  minimum  of  70%  (Table  1).  The  objective
of  65%  participation  hoped  for  in  the  second  cancer  plan  will  not  be  reached  by  the  end
of  2013.  The  recurring  controversies  on  the  inefﬁciency  and  pernicious  effects  of  this
screening  do  not  by  themselves  explain  the  low  participation,  but  doubtless  contribute
to  slowing  the  rise  in  the  participation  rate  which  has  been  seen  since  2004.  Indeed,
despite  the  very  positive  results  of  randomized  trials  of  the  1980s  on  the  reduction  in
mortality  speciﬁcally  due  to  breast  cancer  resulting  from  setting  up  screening  campaigns,
∗ Corresponding author.
E-mail address: scientiﬁque@o-lambret.fr (L. Ceugnart).
2211-5684/$ — see front matter © 2013 Éditions françaises de radiologie. Published by Elsevier Masson SAS. All rights reserved.
http://dx.doi.org/10.1016/j.diii.2013.08.005
356  
Table  1  Early  indicators  of  the  efﬁcacy  of  a  screening
program.
Indicators  European  French  (2008)
Rate  of  cancers
detected
Prevalence  >  5/1000  7.7/1000
Incidence >  3/1000  5.8/1000
Rate  of  cancer
in situ
<  20% 14%
Rate  of
cancer  <  10  mm
>  20% 38%
Rate  of  N0
cancers
>  70%  77%
Participation
rate
>  70%  52%  (2011)


























































































peutic management  is  systematically  offered  for  any  proventudies  and  publications  on  the  negative  effects  of  screening
lack of  impact  on  mortality,  overdiagnosis,  false  posi-
ives) have  been  discussed  by  the  media  and  again  quite
ecently by  the  monthly  consumer  magazine  Que  Choisir
2]. The  health  profession  had  not  waited  for  these  articles
o question  the  possible  undesirable  effects  of  this  public
ealth program  and  its  consequences,  as  was  illustrated  by
he subject  of  the  French  Breast  Disease  Society  congress
n Marseilles  in  2011  which  focused  on  overdiagnosis  and
vertreatment. In  2012,  the  results  of  two  independent
orking groups  [3,4]  were  published  in  answer  to  the  detrac-
ors of  mammography  screening.  These  data  need  to  be
nown in  order  to  provide  clear  answers,  ﬁrstly  to  women
ho, justiﬁably,  are  questioning  the  advantages  and  disad-
antages of  this  public  health  measure,  but  also  to  all  those
nvolved in  healthcare.
The  controversy  over  screening  is  centered  on  three  main
oints —  the  impact  on  speciﬁc  mortality,  overdiagnosis  and
alse positives.
rganized screening and mortality
he  Cochrane  Collaboration  meta-analyses  published  for  the
rst time  in  2001  and  updated  several  times  since  [5—7]
eport a  reduction  in  the  relative  risk  of  mortality  of  approx-
mately 10%,  i.e.,  one  life  saved  for  2000  women  at  the  cost
f 200  false  positives  and  10  cases  of  overdiagnosis.  These
stimates are  therefore  very  different  from  the  results  of
he large  multicenter,  prospective,  randomized  trials  and
he meta-analysis  published  in  1995,  which  had  reported  a
eduction in  the  relative  risk  of  mortality  from  breast  cancer
f approximately  30%  [8].  In  a  recent  paper,  from  analyzing
he incidence  and  mortality  in  a  Danish  database,  Jorgensen
t al.  even  concluded  that  the  reduction  in  mortality  was
reater in  the  non-screened  group  than  in  the  screened
roup, respectively  2  and  1%  [9].  A  Norwegian  study  has
hown that  the  reduction  in  the  number  of  deaths  recorded
etween two  counties,  one  with  and  the  other  without  a
creening program,  was  estimated  to  be  around  18%,  10%
f which  was  put  down  to  improvements  in  treatment  and
anagement [11].
c
aL.  Ceugnart  et  al.
We  have  known  for  a  long  time  that  it  is  illusory  to  look  for
n overall  reduction  in  mortality  since  death  due  to  breast
ancer only  represents,  at  the  worst,  15%  of  female  mor-
ality according  to  national  data  published  by  the  French
ational Cancer  Institute  (INCa)  [10].
As  regards  speciﬁc  mortality,  the  data  quoted  by  sup-
orters of  the  Cochrane  Collaboration  need  to  be  examined
ery carefully,  since  they  are  not  derived  from  the  results
f randomized  trials  but  from  ‘reasonable  estimates’  that
he authors  have  made,  as  the  excellent  update  provided
y Duffy  and  Paci  in  the  Bulletin  Epidémiologique  Hebdo-
adaire in  September  2012  indicates  [12].  Moreover,  the
umber of  deaths  avoided  is  always  related  in  the  studies
ncluded to  the  number  of  women  invited  to  take  part  in
he program,  rather  than  the  number  of  women  actually
creened [13].  Because  the  rates  of  participation  ﬂuctu-
te between  50  and  80%,  the  ﬁgures  are  totally  different,
arying from  one  death  avoided  for  2000  women  invited
ccording to  the  Cochrane  Collaboration  estimates,  to  one
eath avoided  for  455,  303  or  426  women  having  a  mammo-
ram every  2  years  between  the  age  of  50  and  59,  60  and
9, and  70  and  79  respectively,  according  to  Hendricks  and
elvie [13].  Finally,  in  the  large  majority  of  cases,  death
rom breast  cancer  occurs  many  years  after  the  disease  is
etected, but  most  of  the  work  casting  doubt  on  the  effect
f screening  lacks  the  necessary  period  of  follow-up  (6  years
n the  paper  by  Zahl  et  al.  [14].  Analysis  of  speciﬁc  mortality
n the  Swedish  study  of  two  counties  indeed  shows  that  the
ositive impact  increases  in  the  long-term,  changing  from
6% at  10  years  to  31%  with  29  years  follow-up.  Out  of  the
roup of  65,518  women  who  actually  participated  (85%  of
he 77,080  invited),  158  deaths  were  avoided,  correspond-
ng to  a reduction  in  mortality  equivalent  to  one  life  spared
or 300  women  screened  for  10  years  [15].
verdiagnosis
eﬁnition
he  deﬁnition  of  overdiagnosis  varies  from  one  author  to
nother. For  some,  it  is  the  discovery  by  screening  of  a
ancer which  will  not  be  responsible  for  the  death  of
he individual,  for  others  it  is  the  discovery  of  a  cancer
hich would  not  have  been  diagnosed  during  the  individ-
al’s lifetime  if  there  had  been  no  screening.  This  latter
ess restrictive  deﬁnition  takes  into  account  all  the  negative
personal, familial  or  social)  effects  of  the  discovery  and
reatment of  a  cancer.
Overdiagnosis is  a  problem  which  has  to  be  taken  into
ccount essentially  because  of  the  treatments  which  follow
rom it.  Overtreatment  is  treatment  of  ‘overdiagnosed’  can-
ers and  is  obviously  the  most  important  undesirable  effect.
ndeed, in  the  present  state  of  French  and  international
uidelines, in  the  absence  of  exceptional  clinical  situations
r objective  evidence  (from  imaging,  histology,  laboratory
ests, etc.)  allowing  a  potentially  evolutive  cancer  to  be
ifferentiated from  one  which  would  remain  stable,  thera-ase of  breast  cancer.
Overdiagnosis is  not  speciﬁc  to  breast  cancer  but  has
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all,  the  prostate  [16].  Reﬂection  on  this  issue  is  underway
in other  areas  and  concerns  any  radiological,  laboratory  or
functional investigation  where  the  consequences  need  to  be
fully grasped  by  the  prescribers.
Estimation
Estimates  of  the  level  of  overdiagnosis  vary  widely  in  the
literature from  1  to  75%  [11,16].  For  the  detractors  of
screening, the  rate  is  greater  than  25%,  with  some  even
considering that  all  carcinomas  in  situ  are  actually  overdiag-
noses. Obviously,  it  depends  on  the  type  of  cancers  taken
into account  (just  an  invasive  lesion  or  combined  with  an
in-situ lesion)  and  also  on  the  calculation  method  (a  com-
parative analysis  of  incidence  and  mortality  data  in  regions
or countries  with  and  without  screening  campaigns,  over
identical or  different  time-scales,  the  duration  of  the  lead-
time bias  [early  diagnosis  due  to  screening  which  artiﬁcially
increases survival  time  compared  with  survival  of  a  patient
in whom  a  lesion  is  discovered  clinically]).
The  three  main  points  in  favor  of  overdiagnosis  are:
• the very  considerable  increase  in  the  incidence  of  breast
cancer  over  the  last  20  years  without  any  rise  in  mortality
which  cannot  be  explained  only  by  therapeutic  improve-
ment.  From  analyzing  the  incidence  of  breast  cancer  in
France  in  cohorts  of  women  born  in  three  different  periods
(1911—1915,  1926—1930,  1941—1945),  Junod  et  al.  found
an  increase  of  76  and  23%  respectively  in  incidence
between  50  to  65  years  old  and  65  to  79  years  old,  with  no
modiﬁcation  in  speciﬁc  mortality  [17].  This  type  of  anal-
ysis  is  not  however  reliable  because,  as  reported  by  the
EUROSCREEN  working  group,  the  comparison  of  cohorts
in  different  periods,  regions  or  socio-economic  conditions
produces  major  bias  particularly  linked  to  different  risk
factors  and  the  cohort  effect  [3].  The  cumulative  risk
from  0  to  74  years  of  age  of  death  through  breast  cancer
of  a  woman  born  in  France  in  1910  was  approximately  5%,
whereas  it  is  more  than  12%  for  a  woman  born  in  1980  [18].
In  other  situations,  comparison  of  the  incidence  before
and  after  introducing  screening  in  the  same  population
induces bias  connected  with  the  group  ageing.  Finally,  in
all  the  cohort  studies  there  is  the  problem  of  contami-
nation of  the  control  group  by  patients  who  also  have
mammograms  and  therefore  beneﬁt  from  them  without
being  counted  in  the  group  screened;
• the absence  of  reduction  in  the  incidence  of  cancer  at
the  end  of  the  screening  period:  logically  if  screening
discovers subclinical  lesions  earlier,  a  decrease  in  inci-
dence  should  be  seen  during  the  ﬁrst  years  after  stopping
screening.  Jørgensen  et  al.  state  that  this  has  never
been found  [19].  However,  in  a  paper  published  in  2012,
Kalager  et  al.,  authors  who  cannot  be  considered  as  pro-
screening,  showed  a  reduction  of  14%  in  incidence  in  the
4  years  following  the  end  of  screening  in  a  Norwegian  pop-
ulation  [20];
• absence  of  reduction  in  advanced  stages  of  breast  can-
cer:  this  third  argument  has  been  reported  principally  by
Autier  et  al.  [21]  who,  from  a  study  of  published  data  from
the  registers  of  four  countries  (Northern  Ireland,  Scot-
land,  USA  and  Tasmania),  have  shown  the  rate  of  advanced
stage  cancer  (larger  than  2  cm,  stage  II  and  higher,  1  lym-





7  years  of  screening  and  participation  of  more  than  60%.
The  authors  concluded  that  mammography  mainly  detects
non-evolving  subclinical  lesions  and  does  not  detect  more
aggressive  cancers.  These  results  are  completely  opposite
to  the  results  published  by  an  English  team  from  analy-
sis  of  survival  at  10  years  of  two  cohorts  of  7700  patients
treated  for  subclinical  cancer,  compared  with  more  than
11,000  women  who  had  a  ‘symptomatic’  cancer  (and  not
as  the  study  mentioned  above,  from  an  analysis  of  the
results  of  seven  randomized  trials)  [22].  The  rate  for  can-
cer  of  more  than  30  mm  was  6.4%  in  the  screened  group  as
against  21%  among  the  controls.  When  the  rate  of  lymph
node  invasion  was  considered  (whatever  the  size  of  the
lesion),  it  was  28%  and  50%  respectively.  Survival  was
obviously  positively  correlated  with  the  method  of  detec-
tion  since  the  screened  women  had  survival  at  10  years
estimated  as  77%  taking  into  account  the  lead  time  effect,
i.e.  a  gain  of  12.5%  relative  to  the  symptomatic  women.
he EUROSCREEN data and the independent
nglish  analysis
n  view  of  the  controversy  concerning  the  negative  effects
f organized  screening  programs  produced  by  the  many
apers published  over  the  last  few  years  and  the  virulence  of
omments published  in  prestigious  journals  [23],  additional
nalyses were  undertaken  and  published  in  2012.
UROSCREEN working group review [3]
his  European  working  group  is  comprised  of  a  number  of
pidemiologists, some  of  whom  take  part  in  their  national
creening programs.  Review  of  their  mutual  analyses  of
ublished data  (17  trend  analysis  studies,  20  studies  of  the
ncidence of  mortality  and  eight  case-control  studies)  shows
hat reduction  in  mortality  resulting  from  organized  pro-
rams for  the  studies  based  on  incidence  is  estimated  as
eing between  25  and  38%  respectively  for  the  status  of
invited to  participate’  or  ‘participating’.  For  the  case-
ontrol studies  (a  patient  with  mammography  screening
ersus a  patient  without  screening),  the  reduction  was  still
reater, estimated  at  31%  and  48%  after  adjustment  for  self-
election bias  (which  exists  if  the  patients  themselves  chose
o be  in  the  screened  group  and  were  not  randomly  assigned
o a  group).
As regards  overdiagnosis,  this  was  estimated  from
3 studies  undertaken  in  seven  European  countries  to  be
etween 1  and  10%  depending  on  analysis  methods  and
djustment to  the  risk  of  cancer  and  advancement  at  diag-
osis. In  almost  all  the  work  published  that  was  taken  into
ccount, there  was  no  such  adjustment,  which  explains
he differences  in  rates;  thus,  in  the  work  on  the  English
nd Welsh  cohorts  published  by  Jorgensen  and  Gotzsche  in
009 [24]  the  rate  of  overdiagnosis  was  estimated  as  being
etween 41  and  57%  (respectively,  for  invasive  or  invasive
nd in  situ  combined).  Following  adjustment,  this  rate  was
0% [3].  Finally,  the  risk  of  a  false  positive  (unnecessary
ecall, biopsy  later  found  to  be  benign)  was  estimated  at
0% (17%  for  recall  and  3%  for  interventional  procedures)
or 10  years  follow-up  with  a  mammogram  every  2  years  [3].
358  
Result of the independent United Kingdom
analysis  [4]
British  pragmatism  was  again  demonstrated  when,  following
virulent attacks  against  screening  and  remarks  concern-
ing conﬂicts  of  interest  for  all  the  pro-screening  authors,
the regulatory  authorities  appointed  an  independent  review
panel to  analyze  the  results  chaired  by  Sir  Michael  Marmott.
This renowned  epidemiologist  has  never  worked  in  breast
cancer screening.
The conclusions  of  analysis  of  the  results  of  the  10  ran-
domized studies  considered  in  the  Cochrane  review  (after
excluding the  Edinburgh  study  for  major  bias)  [7]  conﬁrmed
a reduction  of  20%  in  the  relative  risk  of  speciﬁc  mortal-
ity produced  by  screening  programs.  Considering  that  these
ﬁrst studies  were  more  than  30  years  old,  they  also  ana-
lyzed the  results  of  recent  English  observational  studies
(case-control and  trend  analysis),  which  showed  still  greater
beneﬁt (without  giving  precise  ﬁgures  because  the  group  had
some reservations  concerning  potential  bias  in  these  stud-
ies). This  was  found  in  the  previously  described  English  study
of survival  at  10  years  published  by  Allgood  et  al.  in  2012
[22].
The rate  of  overdiagnosis,  from  three  randomized  studies
(Malmo I,  Canada  I  and  II),  was  estimated  at  between  11  and
19%.
In absolute  values,  for  10,000  women  invited  to  be
screened from  the  age  of  50  for  the  next  20  years  with  a
mammogram every  3  years  (the  English  program),  43  deaths
will be  avoided.  That  amounts  to  one  life  saved  for
235 women  invited  and  for  180  taking  part,  far  beyond  the
Cochrane Collaboration  estimate  (one  death  avoided  for
2000 women  invited).  These  results  agree  with  those  pub-
lished in  2011  by  the  American  preventive  task  force  [25]  and
are summarized  in  Table  2.  On  the  other  hand,  in  the  same
population and  over  the  same  period  of  time,  129  cancers
(invasive and  in  situ)  seemed  to  correspond  to  overdiagno-
sis. That  may  seem  considerable,  but  for  the  307,000  English
women in  the  50  to  52-year-old  age  group,  represents  a
cumulative risk  over  the  next  20  years  of  less  than  1%.
Table  2  Evaluation  of  the  number  of  patients  to  be
screened  to  ‘save’  one  life.
Description  of  the  method  Number  of  women
Independent  English  review  2012  [4]
RR reduced  by  20%.
50—79 years  old
235 invited
180 screened
Cochrane Collaboration  2011  [7]
Reduced AR  based  on  13  years
of  follow-up  of  randomized
trials
2000  invited
US Preventive  Task  Force  2009  [25]
Based on  7  years  of  screening
and  13  years  follow-up
1339 invited  aged
50—59
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ther points which have not been
ddressed
he disadvantages of organized screening: the
roblem  of false positives
n  this  review,  we  have  only  addressed  the  arguments  con-
erning the  reduction  in  mortality  and  overdiagnosis,  but
he risks  of  false  positives  at  the  ﬁrst  and  second  readings
hould not  be  forgotten.  In  the  literature,  their  frequency
s estimated  at  between  3 and  17%  (resulting  in  recalls  after
2 and  sometimes  interventional  procedures)  [3].  However,
hese ﬁgures  cannot  be  transposed  to  the  French  system
ince our  radiologists  can  provide  an  immediate  diagnostic
ssessment (IDA)  on  detecting  an  abnormality  in  a  screening
xamination. In  2009,  therefore,  from  positive  screening  of
.4% before  assessment  (which  is  in  line  with  the  European
ecommended recall  rate)  the  rate  is  reduced  to  1.3%  sus-
ect diagnoses  after  the  IDA  [26],  this  rate  being  similar  to
he rate  estimated  by  the  EUROSCREEN  experts  [3].
dvantages of the organized screening
rogram
imilarly,  we  have  not  considered  the  advantages  of  set-
ing up  these  screening  programs,  such  as  quality  control  of
quipment and  practice,  and  evaluation  of  the  results.  In
erms of  quality  control,  the  obligation  for  all  radiologists
nd operators  to  undergo  speciﬁc  training  in  screening  and
o undertake  daily,  weekly  and  6-monthly  checks  of  mam-
ogram quality  ensures  that  all  women  throughout  French
erritory receive  very  high  quality  service.  Finally,  annual
valuation of  screening  campaigns  gives  the  authorities  and
adiologists up-to-date  results  in  terms  of  mammography
echnique (analogical  versus  digital,  dose  delivered),  detec-
ion, diagnosis  and  follow-up  of  women  screened.  None  of
he criticisms  from  the  detractors  of  this  type  of  program
ould be  possible  if  there  was  no  such  evaluation  process
as is  shown  by  the  absence  of  possible  analysis  of  the  per-
ormance of  individual  screening).
onclusion
etting  up  public  health  screening  programs  has  advantages
nd disadvantages.  In  view  of  recently  published  indepen-
ent work  on  organized  breast  cancer  screening  in  women
etween 50  and  75  years  of  age,  it  appears  that  the  dis-
dvantages (overdiagnosis,  false  positives,  irradiation)  do
ot challenge  the  usefulness  of  this  program  which,  at  the
ery least,  results  in  a  20%  reduction  in  the  relative  risk
f speciﬁc  mortality.  It  is  important  for  all  health  profes-
ionals to  be  aware  of  these  data  and  to  explain  to  their
atients, in  a  clear  and  honest  fashion,  the  positive  side  of
his type  of  screening  without  hiding  the  negative  effects.
octors should  not  advise  women  to  refuse  to  take  part  in
his public  health  program  because  of  possible  undesirable
ffects, since  the  balance  between  the  beneﬁts  and  risks
s in  favor  of  screening.  If  a  woman  who  is  fully  informed
efuses screening  that  is  then  an  individual  decision  which
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to  propose  an  individual  mammography  examination,  which
will not  avoid  any  of  the  previous  disadvantages  (since  they
are not  due  to  the  screening  program  but  to  the  mammo-
gram itself)  but  in  addition  will  expose  the  patient  to  an
increased risk  of  a  false  negative  because  there  will  be  no
second reading.  Future  hopes  are  for  genomic  analysis  and
molecular biology  techniques  which  will  probably  provide
answers to  the  problem  not  resolved  by  current  methods
(imaging, histology,  laboratory  tests  or  clinical  examination)
of non  or  hardly  evolving  cancers  deﬁned  as  overdiagnoses
and resulting  in  overtreatment.
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